Retrieve available abstracts of 47 articles: HTML format
Single Articles
February 2025
Global, regional, and national prevalence of adult overweight and obesity,
1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of
Disease Study 2021.
Lancet. 2025 Feb 28:S0140-6736(25)00355-1. doi: 10.1016/S0140-6736(25)00355. PubMedAbstract available
Global, regional, and national prevalence of child and adolescent overweight and
obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global
Burden of Disease Study 2021.
Lancet. 2025 Feb 28:S0140-6736(25)00397-6. doi: 10.1016/S0140-6736(25)00397. PubMedAbstract available
SORENSEN TIA Forecasting the global obesity epidemic through 2050.
Lancet. 2025 Feb 28:S0140-6736(25)00260-0. doi: 10.1016/S0140-6736(25)00260. PubMed
January 2025
HORTON R Offline: Making obesity matter.
Lancet. 2025;405:284. PubMed
KLOPPENBURG M, Namane M, Cicuttini F Osteoarthritis.
Lancet. 2025;405:71-85. PubMedAbstract available
November 2024
KIRBY T Brazil considers obesity discrimination law.
Lancet. 2024;404:1912-1913. PubMed
SEBERT S The obesity crisis in the USA: why are there no signs of plateauing yet?
Lancet. 2024 Nov 12:S0140-6736(24)02467-X. doi: 10.1016/S0140-6736(24)02467. PubMed
National-level and state-level prevalence of overweight and obesity among
children, adolescents, and adults in the USA, 1990-2021, and forecasts up to
2050.
Lancet. 2024 Nov 12:S0140-6736(24)01548-4. doi: 10.1016/S0140-6736(24)01548. PubMedAbstract available
October 2024
EZZATI M, Zhou B, Bennett JE, Phelps NH, et al Assessing worldwide trends of underweight and obesity - Authors' reply.
Lancet. 2024;404:1644. PubMed
BOMBAK A, Riediger N Assessing worldwide trends of underweight and obesity.
Lancet. 2024;404:1643. PubMed
CHRISTENSEN DL, Bygbjerg IC Assessing worldwide trends of underweight and obesity.
Lancet. 2024;404:1642. PubMed
CZERNICHOW S, Ziegler O, Clement K, Coupaye M, et al Assessing worldwide trends of underweight and obesity.
Lancet. 2024;404:1642-1643. PubMed
VAN STEIJVOORT E, Borry P Assessing worldwide trends of underweight and obesity.
Lancet. 2024;404:1641-1642. PubMed
August 2024
General and abdominal adiposity and hypertension in eight world regions: a pooled
analysis of 837 population-based studies with 7.5 million participants.
Lancet. 2024;404:851-863. PubMedAbstract available
NASIR K Embracing the duality of BMI and central adiposity.
Lancet. 2024;404:824-825. PubMed
KOSIBOROD MN, Deanfield J, Pratley R, Borlaug BA, et al Semaglutide versus placebo in patients with heart failure and mildly reduced or
preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF,
and STEP-HFpEF DM randomised trials.
Lancet. 2024 Aug 29:S0140-6736(24)01643-X. doi: 10.1016/S0140-6736(24)01643. PubMedAbstract available
DEANFIELD J, Verma S, Scirica BM, Kahn SE, et al Semaglutide and cardiovascular outcomes in patients with obesity and prevalent
heart failure: a prespecified analysis of the SELECT trial.
Lancet. 2024;404:773-786. PubMedAbstract available
LINGVAY I, Cohen RV, Roux CWL, Sumithran P, et al Obesity in adults.
Lancet. 2024 Aug 16:S0140-6736(24)01210-8. doi: 10.1016/S0140-6736(24)01210. PubMedAbstract available
May 2024
MORIN-PAPUNEN L Bariatric surgery in women with PCOS and obesity.
Lancet. 2024 May 20:S0140-6736(24)00811-0. doi: 10.1016/S0140-6736(24)00811. PubMed
SAMARASINGHE SNS, Leca B, Alabdulkader S, Dimitriadis GK, et al Bariatric surgery for spontaneous ovulation in women living with polycystic ovary
syndrome: the BAMBINI multicentre, open-label, randomised controlled trial.
Lancet. 2024 May 20:S0140-6736(24)00538-5. doi: 10.1016/S0140-6736(24)00538. PubMedAbstract available
April 2024
THE LANCET EDITORS Retraction and republication-Pharmacotherapy for adults with overweight and
obesity: a systematic review and network meta-analysis of randomised controlled
trials.
Lancet. 2024;403:1321. PubMed
SHI Q, Wang Y, Hao Q, Vandvik PO, et al Pharmacotherapy for adults with overweight and obesity: a systematic review and
network meta-analysis of randomised controlled trials.
Lancet. 2024;403:e21-e31. PubMedAbstract available
BUTLER J, Shah SJ, Petrie MC, Borlaug BA, et al Semaglutide versus placebo in people with obesity-related heart failure with
preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF
DM randomised trials.
Lancet. 2024 Apr 4:S0140-6736(24)00469-0. doi: 10.1016/S0140-6736(24)00469. PubMedAbstract available
DONAL E, L'Official G, Istratoaie S Semaglutide-a new treatment for obesity-related heart failure with preserved
ejection fraction?
Lancet. 2024 Apr 4:S0140-6736(24)00653-6. doi: 10.1016/S0140-6736(24)00653. PubMed
March 2024
JOHANSSON K, Bodnar LM, Stephansson O, Abrams B, et al Safety of low weight gain or weight loss in pregnancies with class 1, 2, and 3
obesity: a population-based cohort study.
Lancet. 2024 Mar 28:S0140-6736(24)00255-1. doi: 10.1016/S0140-6736(24)00255. PubMedAbstract available
GAILLARD R Optimising gestational weight gain among pregnant women with obesity.
Lancet. 2024 Mar 28:S0140-6736(24)00470-7. doi: 10.1016/S0140-6736(24)00470. PubMed
February 2024
TUMAS N, Lopez SR Double burden of underweight and obesity: insights from new global evidence.
Lancet. 2024 Feb 29:S0140-6736(24)00051-5. doi: 10.1016/S0140-6736(24)00051. PubMed
Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis
of 3663 population-representative studies with 222 million children, adolescents,
and adults.
Lancet. 2024 Feb 29:S0140-6736(23)02750-2. doi: 10.1016/S0140-6736(23)02750. PubMedAbstract available
CAMPBELL P, Rutten FH, Lee MM, Hawkins NM, et al Heart failure with preserved ejection fraction: everything the clinician needs to
know.
Lancet. 2024 Feb 14:S0140-6736(23)02756-3. doi: 10.1016/S0140-6736(23)02756. PubMedAbstract available
January 2024
THE LANCET Treating obesity and diabetes: drugs alone are not enough.
Lancet. 2024;403:1. PubMed
ZOU M, Northstone K, Leary S Causal effects of later-eating rhythm on adiposity in children through the
comparison of two cohorts in the UK and China: a cross-cohort study.
Lancet. 2023;402 Suppl 1:S99. PubMedAbstract available
ALRUBAIAN F, Mulla Z Governments policy measures to address obesity among adults: a scoping review of
the global evidence.
Lancet. 2023;402 Suppl 1:S20. PubMedAbstract available
CISNEROS AB, Headings R, Wells R, Reynolds C, et al Understanding the use of media analysis in public health research through food
tax debates (HEALTHEI Project): a scoping review.
Lancet. 2023;402 Suppl 1:S9. PubMedAbstract available
SPAVIN A, Moore A, Lunn J, Tucker F, et al Reflecting on parental insights into healthy lifestyles: a qualitative study.
Lancet. 2023;402 Suppl 1:S85. PubMedAbstract available
CHEN S, Kuper H Tracing the temporal trends of modifiable risk factors in dementia: insights from
the English Longitudinal Study of Ageing (2004-2019).
Lancet. 2023;402 Suppl 1:S34. PubMedAbstract available
WALSH S, Wallace L, Kuhn I, Mytton O, et al Population-level interventions for the primary prevention of dementia: a complex
evidence review.
Lancet. 2023;402 Suppl 1:S13. PubMedAbstract available
October 2023
KOTANI T, Tano S Long-term effects of gestational weight gain on mortality.
Lancet. 2023 Oct 19:S0140-6736(23)01837-8. doi: 10.1016/S0140-6736(23)01837. PubMed
HINKLE SN, Mumford SL, Grantz KL, Mendola P, et al Gestational weight change in a diverse pregnancy cohort and mortality over 50
years: a prospective observational cohort study.
Lancet. 2023 Oct 19:S0140-6736(23)01517-9. doi: 10.1016/S0140-6736(23)01517. PubMedAbstract available
September 2023
SUMITHRAN P, Finucane FM, Cohen RV Obesity drug shortages are symptomatic of wider malaise.
Lancet. 2023 Sep 29:S0140-6736(23)01963-3. doi: 10.1016/S0140-6736(23)01963. PubMed
June 2023
GARVEY WT, Frias JP, Jastreboff AM, le Roux CW, et al Tirzepatide once weekly for the treatment of obesity in people with type 2
diabetes (SURMOUNT-2): a double-blind, randomised, multicentre,
placebo-controlled, phase 3 trial.
Lancet. 2023 Jun 26:S0140-6736(23)01200-X. doi: 10.1016/S0140-6736(23)01200. PubMedAbstract available
APOVIAN CM, McDonnell ME CagriSema and the link between obesity and type 2 diabetes.
Lancet. 2023 Jun 23:S0140-6736(23)01291-6. doi: 10.1016/S0140-6736(23)01291. PubMed
KNOP FK, Aroda VR, do Vale RD, Holst-Hansen T, et al Oral semaglutide 50 mg taken once per day in adults with overweight or obesity
(OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2023 Jun 23:S0140-6736(23)01185-6. doi: 10.1016/S0140-6736(23)01185. PubMedAbstract available
FALLOWS E, Ells L, Anand V Semaglutide and the future of obesity care in the UK.
Lancet. 2023 Jun 5:S0140-6736(23)01083-8. doi: 10.1016/S0140-6736(23)01083. PubMed
May 2023
SKYLE D Fatima Cody Stanford: changing the narrative on obesity.
Lancet. 2023;401:1644. PubMed
April 2023
MAHGOUB S, Newsome PN Bariatric-metabolic surgery versus lifestyle intervention in non-alcoholic
steatohepatitis.
Lancet. 2023 Apr 20:S0140-6736(23)00773-0. doi: 10.1016/S0140-6736(23)00773. PubMed
VERRASTRO O, Panunzi S, Castagneto-Gissey L, De Gaetano A, et al Bariatric-metabolic surgery versus lifestyle intervention plus best medical care
in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised
trial.
Lancet. 2023 Apr 20:S0140-6736(23)00634-7. doi: 10.1016/S0140-6736(23)00634. PubMedAbstract available